Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 18/20 | 0.50 |
| ▸ | CA1 | P00915 | 17/20 | 0.50 |
| ▸ | CA7 | P43166 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA4 | P22748 | 4/20 | 0.50 |
| ▸ | CA6 | P23280 | 4/20 | 0.50 |
| ▸ | CA5A | P35218 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.44 |
| ▸ | CA3 | P07451 | 3/20 | 0.44 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16400832 | 0.86 | CA2 (0.53) | PTGES2CA2CA1CA7CA12 | |
| SCHEMBL1804856 | 0.85 | PTGES2 (0.51) | PTGES2CA2CA1CA7CA12 | |
| SCHEMBL18535935 | 0.83 | CA1 (0.48) | CA2CA1CA7CA12CA4 | |
| SCHEMBL15881385 | 0.83 | PTGES2 (0.43) | PTGES2CA2CA1CA7CA12 | |
| SCHEMBL29707969 | 0.83 | PTGES2 (0.43) | PTGES2CA2CA1CA7CA12 | |
| SCHEMBL7194983 | 0.81 | CA1 (0.47) | CA2CA1CA7CA12CA4 | |
| Hydrochloric Acid SCHEMBL28301073 | 0.81 | PTGES2 (0.42) | PTGES2CA2CA1CA7CA12 | |
| SCHEMBL289875 | 0.81 | CA2 (0.50) | CA2CA1CA7CA12CA4 | |
| SCHEMBL1013610 | 0.81 | GSTO1 (0.44) | PTGES2CA2CA1CA7CA12 | |
| SCHEMBL28873594 | 0.81 | CA2 (0.53) | PTGES2CA2CA1CA7CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2984072-B1 | SYNTHETIC ANALOGUES OF XANTHOHUMOL | UNIV PISA (IT) | 2024-05-29 | — | — | EP | disclosed |
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-9822092-B2 | ArylSulfonamide-based matrix metalloprotease inhibitors | NOVARTIS AG (CH) | 2017-11-21 | — | — | US | disclosed |
| US-9617213-B2 | Synthetic analogues of xanthohumol | UNIVERSITA' DI PISA (IT) | 2017-04-11 | — | — | US | disclosed |
| US-9617213-B2 | Synthetic analogues of xanthohumol | UNIVERSITA' DI PISA (IT) | 2017-04-11 | — | — | US | disclosed |
| US-9617213-B2 | Synthetic analogues of xanthohumol | UNIVERSITA' DI PISA (IT) | 2017-04-11 | — | — | US | disclosed |
| US-20160159805-A1 | Heterocyclic sulfonylamino(thio)carbonyl-derivatives with nematicidal properties | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20160159805-A1 | Heterocyclic sulfonylamino(thio)carbonyl-derivatives with nematicidal properties | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | US | disclosed |
| US-20160159805-A1 | Heterocyclic sulfonylamino(thio)carbonyl-derivatives with nematicidal properties | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-06-09 | — | — | US | disclosed |
| WO-2009118292-A1 | ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| US-7592357-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1718638-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080058384-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1718638-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082890-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
| EP-1268494-A1 | SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS | Merck Frosst Canada & Co. (CA) | 2003-01-02 | — | — | EP | disclosed |
| US-6498151-B2 | PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-12-24 | — | — | US | disclosed |
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-07-11 | — | — | US | disclosed |
| WO-2001070753-A1 | SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058384-A1 | Novel Compounds | ARHGDIB, TNK2, ROCK2 | PTGES2 2069/4885CA2 3526/4885CA1 4821/4885 |
| US-20160159805-A1 | Heterocyclic sulfonylamino(thio)carbonyl-derivatives with nematicidal properties | TST, TUBB, TUBA3C | PTGES2 650/4885CA2 2143/4885CA1 3866/4885 |
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | PTPRF, PTPRS, PTPRO | PTGES2 2326/4885CA2 2577/4885CA1 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.